In a large, multicentered cohort study of 548 NSMs performed on 346 BRCA1/2 carriers across nine institutions in the United States, no new breast cancers were diagnosed on the side of the procedure at a median follow-up of 34 months [67]. This evidence concerns the gene BRCA1 and breast cancer.